[go: up one dir, main page]

AU2003209059A1 - Human monoclonal antibodies against membrane proteins - Google Patents

Human monoclonal antibodies against membrane proteins

Info

Publication number
AU2003209059A1
AU2003209059A1 AU2003209059A AU2003209059A AU2003209059A1 AU 2003209059 A1 AU2003209059 A1 AU 2003209059A1 AU 2003209059 A AU2003209059 A AU 2003209059A AU 2003209059 A AU2003209059 A AU 2003209059A AU 2003209059 A1 AU2003209059 A1 AU 2003209059A1
Authority
AU
Australia
Prior art keywords
monoclonal antibodies
antibodies against
human monoclonal
membrane proteins
against membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003209059A
Other languages
English (en)
Other versions
AU2003209059A8 (en
Inventor
Shaobing Hua
Michelle H. Pauling
Li Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetastix Corp
Original Assignee
Genetastix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/072,031 external-priority patent/US6766082B2/en
Priority claimed from US10/071,866 external-priority patent/US20030165988A1/en
Application filed by Genetastix Corp filed Critical Genetastix Corp
Publication of AU2003209059A1 publication Critical patent/AU2003209059A1/en
Publication of AU2003209059A8 publication Critical patent/AU2003209059A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003209059A 2002-02-08 2003-02-07 Human monoclonal antibodies against membrane proteins Abandoned AU2003209059A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/071,866 2002-02-08
US10/072,031 2002-02-08
US10/072,031 US6766082B2 (en) 2000-10-18 2002-02-08 Waveguide-type optical device and manufacturing method therefor
US10/071,866 US20030165988A1 (en) 2002-02-08 2002-02-08 High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US13397802A 2002-04-25 2002-04-25
US10/133,978 2002-04-25
PCT/US2003/003763 WO2003066830A2 (fr) 2002-02-08 2003-02-07 Anticorps monoclonaux humains diriges contre des proteines membranaires

Publications (2)

Publication Number Publication Date
AU2003209059A1 true AU2003209059A1 (en) 2003-09-02
AU2003209059A8 AU2003209059A8 (en) 2009-07-30

Family

ID=27738990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003209059A Abandoned AU2003209059A1 (en) 2002-02-08 2003-02-07 Human monoclonal antibodies against membrane proteins

Country Status (2)

Country Link
AU (1) AU2003209059A1 (fr)
WO (1) WO2003066830A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1766017T3 (pl) * 2004-06-10 2015-08-31 Viventia Bio Inc Przeciwciało specyficzne wobec nowotworu
WO2006068646A1 (fr) * 2004-12-20 2006-06-29 Xiaoming Chen Méthodes d'identification et d'isolement d'anticorps spécifiques d'un épitope
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
EP2054086A1 (fr) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG Conjugué d'un anticorps dirigé contre le ccr5 et peptide antifusiogène
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009002694A (es) 2006-09-29 2009-03-24 Hoffmann La Roche Anticuerpos dirigidos contra ccr5 y usos de los mismos.
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010021697A2 (fr) 2008-08-18 2010-02-25 Pfizer Inc. Anticorps anti-ccr2
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2011117423A1 (fr) 2010-03-26 2011-09-29 Ablynx N.V. Domaines variables uniques de l'immunoglobuline dirigés contre cxcr7
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
CN102323423A (zh) * 2011-05-31 2012-01-18 昆明理工大学 检测曲妥珠影响MCF-7细胞中Trx-1蛋白表达的方法
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2970438A4 (fr) 2013-03-15 2016-08-24 Salimetrics Llc Anticorps monoclonal de mélatonine, détection, procédés et utilisations de celui-ci
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Anti-pd-l1 antibodies
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN112646833A (zh) * 2020-11-05 2021-04-13 杭州阿诺生物医药科技有限公司 一种全人源抗体酵母展示技术的设计与构建
US20240327822A1 (en) * 2021-08-12 2024-10-03 The University Of Hong Kong Materials and methods to comprehensively define adaptive immune responses
CN116731165B (zh) * 2023-03-23 2024-08-13 北京巴瑞医疗器械有限公司 一种抗血清素抗体及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
AU3587599A (en) * 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo

Also Published As

Publication number Publication date
AU2003209059A8 (en) 2009-07-30
WO2003066830A2 (fr) 2003-08-14
WO2003066830A3 (fr) 2009-06-18

Similar Documents

Publication Publication Date Title
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
AU2003259294A1 (en) Humanized antibodies against human 4-1bb
AU2003271186A1 (en) Double specific antibodies substituting for functional protein
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
IS7499A (is) Mennsk mótefni gegn beta-amýloíðpeptíðum
AU2003219277A1 (en) Intracellular antibodies
AU2003264009A1 (en) Humanized rabbit antibodies
AU2003242713A1 (en) Complex coacervates containing whey proteins
AU2003253621A1 (en) Modified "s" antibodies
AU2003277832A1 (en) Humanized tissue factor antibodies
AU2003226131A1 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
AU2003226899A1 (en) Human diabetes-mediating proteins
AU2003252075A1 (en) Human immunosuppressive protein
AU2003262638A1 (en) Biotinylation of proteins
AU2003202694A1 (en) Torero protein
AU2003271093A1 (en) Antigen recognizing antibody
AU2003219816A1 (en) Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
AU2003278718A1 (en) Stars-a muscle-specification-binding protein
AU2003270055A1 (en) Neurotransmission-associated proteins
AU2003300785A1 (en) Carbohydrate-associated proteins
AU2002325299A1 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
HK1072719A (en) Human monoclonal antibodies against cd30
AU2003229752A1 (en) Human rhomboid-related protein
AU2003254865A1 (en) Akt2-BINDING PROTEIN
AU2003236908A1 (en) Proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase